Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article

Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024) · Cardiovascular Therapeutics · n=0

RCT evidence detailTrial reference

GRADE ModerateRCT

Study Profile

Design: narrative systematic review of randomized controlled trials comparing heparin and bivalirudin anticoagulation in patients undergoing PCI for STEMI, NSTEMI, and unstable angina (Tangshan Gongren Hospital, China; Wuhan University; Harvard T.H. Chan)
Sample size (n): 0
Intervention: Bivalirudin (synthetic hirudin-derived direct thrombin inhibitor) anticoagulation during PCI
Comparator: Unfractionated heparin (standard reference anticoagulant)
Primary endpoint: Composite of efficacy (ischemic events) and safety (bleeding events) outcomes from major RCTs
Primary result: Bivalirudin generally associated with lower bleeding rates than heparin in PCI for ACS; ischemic outcome equivalence varies by trial and ACS subtype; review reinforces clinical equipoise in some patient subgroups; demonstrates how synthetic hirudin-derivative pharmacology is studied via rigorous Phase-III pathways
Follow-up duration: Variable across cited RCTs (typically 30 days to 1 year)
PMID: 39749045

Key Findings

Bivalirudin generally associated with lower bleeding than heparin in PCI for ACS
Trial-by-trial heterogeneity in ischemic-event outcomes
Bivalirudin is a synthetic hirudin derivative (Angiomax) with established FDA approval
Demonstrates the drug-regulatory pathway distinct from K040187 device pathway
Useful pedagogical reference for explaining FDA drug vs FDA device distinctions

Limitations

Narrative synthesis without quantitative meta-analysis
Cited RCTs span multiple decades and PCI eras
Generalization across STEMI / NSTEMI / unstable angina subgroups limited
No new primary data
Not directly applicable to whole-leech hirudotherapy

Clinical Implications

Wang 2024 provides contemporary clinical-pharmacology context for bivalirudin — the synthetic hirudin derivative — within interventional cardiology. For ASH, the review serves as a regulatory and educational reference for distinguishing FDA-approved drug indications (synthetic hirudin derivatives) from the FDA K040187 device indication (whole-leech therapy). No direct US hirudotherapy clinical-practice implications.

Related Trials

Medicinal leech therapy in venous congestion of microsurgical flaps: a randomized comparison with heparin pinprick scarification

Merlino G, Carbone S, Servillo G, Marletta DA (2020)

Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial

Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021)

Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review

Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011)

Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction

Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014)

← Back to RCT Library